Bispecifics Network
Explore Expert Education & Submit Your Questions
Browse curated content by category, watch featured videos, and submit questions as you learn.
Featured Content
Tampa Experts Weigh the Economics of Bringing Bispecifics to Community Care
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
View Content
Philadelphia Experts Share How Bispecific Delivery in Myeloma Varies by Site
In an AJMC stakeholder interchange, moderator Sandra Susanibar-Adaniya, MD, MS, of Penn Medicine, led academic and community clinicians through the operational, safety, and reimbursement challenges of moving teclistamab-and talquetamab-based regimens into earlier lines of relapsed/refractory multiple myeloma and into outpatient, community-based care.
View Content
91% of Community Oncology Sites Offer Bispecifics Despite Barriers
Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.
View ContentBrowse by Category
Content Library
Advance Planning Eases Bispecific Therapy Burden for Patients
Community oncologists are steadily adopting bispecific antibodies for myeloma, but advance planning and tocilizumab remain key to safe access.
OpenBefore the First Bispecific Dose, Community Practices Need a Playbook
Designated teams, standardized SOPs, and scalable workflows are essential before a community practice's first bispecific dose.
OpenHave a Question?
Submit a question based on the content you're exploring.